The Pulmonary Hypertension Association is offering a two-year grant for junior investigators interested in pulmonary arterial hypertension (PAH) research. The Aldrighetti Award for Young Investigators, supported by a partnership with Janssen Pharmaceuticals, covers salaries and/or supplies up to $40,000 each year.
The latest issue of Advances in Pulmonary Hypertension addresses pulmonary arterial hypertension (PAH) as a systemic disease. “Even in its purest form, the idiopathic or hereditary PAH, the rest of the body is affected when various organs begin suffering from inadequate perfusion, initially with exertion, then even at rest,” says guest editor Ioana R. Preston, M.D. “Even in its purest form, the idiopathic or hereditary PAH, the rest of the body is affected when various organs begin suffering from inadequate perfusion, initially with exertion, then even at rest,” says guest editor Ioana R. Preston, M.D.
A recent Pulmonary Hypertension Association (PHA) webinar unveiled learnings from six studies conducted at PHA 2108 International PH Conference and Scientific Sessions. Doctors shared updates about the studies in the July 29 PHA Live webinar “PHA Research Room Findings.” More than 200 patients and healthy subjects participated in Research Room 2018, sharing data and biological samples with 10 research teams.
Join the Pulmonary Hypertension Association (PHA) at 3:30 p.m. EST Thursday, July 29 for “PHA Research Room Findings.” Hear from scientists and clinicians about Research Room study findings from the 2018 PHA International PH Conference and Scientific Sessions.
Your support group participation might improve your life more than you realize. A recently published study shows that support groups improve meaningful health-related outcomes, such as self-care, pulmonary hypertension symptom management, medication adherence and understanding related medical procedures.
The FDA recently approved Tyvaso (treprostinil) Inhalation Solution to improve exercise ability for people who have PH associated with interstitial lung disease. Manufactured by United Therapeutics, Tyvaso is the first FDA-approved treatment for Group 3 PH.
Vineet Agrawal, M.D., Ph.D., is the 2020 recipient of the Pulmonary Hypertension Association’s Aldrighetti Research Award for Young Investigators. Dr. Agrawal is a physician-scientist and instructor of medicine at Vanderbilt University Medical Center.
A new article based Pulmonary Hypertension Association Registry (PHAR) data suggests body weight plays a complex, important role in pulmonary arterial hypertension (PAH). The article, which recently was published in the Annals of the American Thoracic Society, investigated the effects of patient weight on day-to-day activities.
Learn about the latest discoveries in pulmonary hypertension (PH) research. Join the Pulmonary Hypertension Association (PHA) at 3 p.m. EDT, Oct. 9 for “Advancements in PH Research.” Dr. Todd Bull will provide an update on the scientific discoveries and research that could lead to the next generation of PH therapies.
Does your employer have a matching gift program? If so, you can double your contribution to the Pulmonary Hypertension Association (PHA). Depending on the employer, you might be eligible to provide twice the support for the pulmonary hypertension (PH) community, whether you’re an employee, spouse of an employee or retiree.